CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
7.24BCNY1.07B · vs all stocks (USD)
Revenue (TTM)
396.16MCNY58.75M · vs all stocks (USD)
Profit Margin
-90.30%Beta
0.3850xvs all stocks
52-Week Change
-16.46%vs all stocks
Market Capitalization
7.24BCNY1.07B · vs all stocks (USD)
Enterprise Value
6.24BCNY925.94M · vs all stocks (USD)
Forward P/E
6.84xPrice to Sales (TTM)
18.47xPrice to Book (MRQ)
1.59xEnterprise to Revenue
15.76xEnterprise to EBITDA
-55.96xGross Margin
43.70%Profit Margin
-90.30%Operating Margin
-53.95%Return on Assets (TTM)
-2.41%Return on Equity (TTM)
-9.02%Revenue (TTM)
396.16MCNY58.75M · vs all stocks (USD)
Revenue per Share (TTM)
0.1880CNYUpdated Aug 18, 2026Quarterly Revenue Growth
-0.70%Gross Profit (TTM)
196.55MCNY29.15M · vs all stocks (USD)
EBITDA (TTM)
-111.58MCNY-16.55M · vs all stocks (USD)
Net Income (TTM)
-357.73MCNY-53.05M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-0.73%Operating Cash Flow (TTM)
2.77MCNY410.23K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-249.46MCNY-37.00M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
-63.12MCNYFY2025 · Dec 31, 2025Revenue
396.81MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
173.98MCNYFY2025 · Dec 31, 2025Gross Profit
222.83MCNYFY2025 · Dec 31, 2025Operating Income
-173.53MCNY-25.73M · vs all stocks (USD)
Pre-tax Income
-420.42MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.50MCNYFY2025 · Dec 31, 2025Net Income
-421.93MCNYFY2025 · Dec 31, 2025EBIT
-418.11MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-94.43MCNYFY2025 · Dec 31, 2025Research & Development
82.28MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
132.91MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.13MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
17.22MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.31MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1633CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1633CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
2.12BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
2.12BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-421.93MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
76.51MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-340.71MCNYFY2025 · Dec 31, 2025Free Cash Flow
-576.12MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.76BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-421.93MCNYFY2025 · Dec 31, 2025Other Non-cash Items
48.27MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.66MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
39.60MCNYFY2025 · Dec 31, 2025Capital Expenditures
-235.41MCNYFY2025 · Dec 31, 2025Purchase of Investments
-460.00MCNYFY2025 · Dec 31, 2025Sale of Investments
10.04MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-685.38MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
114.80MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.37MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.48MCNYFY2025 · Dec 31, 2025Other Financing Charges
-131.75MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-20.80MCNYFY2025 · Dec 31, 2025Shares Outstanding
2.10BSharesUpdated Aug 18, 2026Float Shares
1.34BSharesUpdated Aug 18, 2026% Held by Insiders
48.51%vs all stocks
% Held by Institutions
1.14%vs all stocks
Total Cash (MRQ)
1.42BCNY209.94M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.6740CNYUpdated Aug 18, 2026Total Debt (MRQ)
132.91MCNY19.71M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0293xCurrent Ratio (MRQ)
16.69xBook Value per Share (MRQ)
2.19CNYUpdated Aug 18, 2026Total Assets
4.87BCNY722.52M · vs all stocks (USD)
Total Current Assets
2.57BCNYFY2025 · Dec 31, 2025Total Liabilities
299.50MCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.30BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
143.70MCNYFY2025 · Dec 31, 2025Total Current Liabilities
155.80MCNYFY2025 · Dec 31, 2025Cash
1.80BCNYFY2025 · Dec 31, 2025Cash Equivalents
1.21MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.81BCNYFY2025 · Dec 31, 2025Other Short-term Investments
10.08MCNYFY2025 · Dec 31, 2025Accounts Receivable
234.33MCNYFY2025 · Dec 31, 2025Inventory
147.57MCNYFY2025 · Dec 31, 2025Accounts Payable
76.18MCNYFY2025 · Dec 31, 2025Short-term Debt
8.25MCNYFY2025 · Dec 31, 2025Other Current Liabilities
254.13KCNYFY2025 · Dec 31, 2025Long-term Debt
126.53MCNYFY2025 · Dec 31, 2025Common Stock (Book)
801.23MCNYFY2025 · Dec 31, 2025Retained Earnings
3.57BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.57BCNY678.10M · vs all stocks (USD)
52-Week Low
2.75CNYUpdated Aug 18, 202652-Week High
4.93CNYUpdated Aug 18, 202652-Week Change
-16.46%vs all stocks
Beta
0.3850xvs all stocks
50-Day MA
3.23CNYUpdated Aug 18, 2026200-Day MA
3.67CNYUpdated Aug 18, 2026Avg 10-Day Volume
38.89MSharesUpdated Aug 18, 2026Avg 30-Day Volume
38.28MSharesUpdated Aug 18, 2026Diluted EPS (TTM)
-0.1700CNYUpdated Aug 18, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 18.47Revenue Growth YoY: -0.01
High gross margins eroded by operating costsNotable
Gross Margin: 0.44Profit Margin: -0.90
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Changchun BCHT Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lifetech Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Anhui Wanbang Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Akums Drugs & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Kanion Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kuros Biosciences AG
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Blue Jet Healthcare Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alto Neuroscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Eis Eczacıbaşı İlaç ve Sanayi A.Ş.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lexicon Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule